Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ha, H.
Right arrow Articles by Lee, H. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ha, H.
Right arrow Articles by Lee, H. B.
J Am Soc Nephrol 14:S246-S249, 2003
© 2003 American Society of Nephrology

Supplement Article

Reactive Oxygen Species and Matrix Remodeling in Diabetic Kidney

Hunjoo Ha and Hi Bahl Lee

Hyonam Kidney Laboratory, Soon Chun Hyang University, Seoul, Korea.

Correspondence to Dr. Hunjoo Ha, Hyonam Kidney Laboratory, Soon Chun Hyang University, 657 Hannam-dong, Yongsan-ku, Seoul 140-743, Korea. Phone: +82-2-709-9177, +82-2-792-6657; Fax: +82-2-792-5812;


   Abstract
Top
 Abstract
Introduction
 Role of Plasminogen Activator...
 Conclusion
 References
 
ABSTRACT. Excessive deposition of extracellular matrix (ECM) in the kidney is the hallmark of diabetic nephropathy. Although the amount of ECM deposited in the kidney depends on the balance between the synthesis and degradation of ECM, the role of ECM degradation in matrix remodeling has been less well appreciated. High glucose, advanced glycation end products, angiotensin II, and TGF-{beta}1 all increase intracellular reactive oxygen species (ROS) in renal cells and contribute to the development and progression of diabetic renal injury. The role of ROS in increased ECM synthesis has been well documented. ROS may also play a critical role in decreased ECM degradation by mediating high glucose- and TGF-{beta}1-induced inhibition of the proteolytic system, plasmin, and matrix metalloproteinases in the glomeruli. A recent observation suggests that ROS play an important role in tubulointerstitial fibrosis by mediating TGF-{beta}1-induced epithelial-mesenchymal transition (EMT). Accelerated ECM degradation is required to disrupt tubular basement membrane and complete EMT. ROS thus seem to be involved in both decreased and increased ECM degradation. It is not clear how cells determine when and where to increase or decrease ECM degradation in response to ROS. Precise definition of ROS-activated signaling pathways leading to ECM remodeling in the kidney will provide new strategies to prevent or treat diabetic renal injury. E-mail: ha@hkl.ac.kr


   Introduction
Top
 Abstract
 Introduction
Role of Plasminogen Activator...
 Conclusion
 References
 
Excessive deposition of extracellular matrix (ECM) in the glomerular mesangium and tubulointerstitium is closely associated with progressive decline in renal function in diabetes (1,2). The amount of ECM deposited in the kidney depends on the balance between synthesis and degradation of ECM (Figure 1). Although the contribution of enhanced ECM synthesis in diabetic kidney is well recognized, the role of ECM degradation in matrix remodeling has been less well appreciated. The observation that mesangial fractional volume and the thickness of glomerular and tubular basement membranes are significantly reduced in diabetic kidneys 10 yr after pancreas transplantation (3) suggests the reversibility of renal fibrosis and the importance of ECM degradation in ECM remodeling in diabetic kidney. Epithelial-mesenchymal transition (EMT) of tubular epithelial cells is an alternative mechanism involved in tubulointerstitial fibrosis, in which increased ECM degradation is one of the key steps (4–6).



View larger version (19K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Figure 1. ROS and ECM remodeling in diabetic kidney.

 
High glucose (7), advanced glycation end products (AGE) (8,9), angiotensin II (Ang II) (10), and TGF-{beta}1 (11) all increase intracellular reactive oxygen species (ROS) in renal cells and contribute to the development and progression of diabetic renal injury. The role of ROS in increased ECM synthesis in diabetic kidney has previously been reviewed (12). In this article, we review the evidence that ROS also play a critical role in both decreased ECM degradation and induction of EMT leading to glomerular mesangial expansion and tubulointerstitial fibrosis in diabetic kidney (Table 1).


View this table:
[in this window]
[in a new window]

  		Table 1. Evidence for critical role of ROS in ECM remodeling in diabetic kidneya
 

   Role of Plasminogen Activator Inhibitor-1 and Plasmin in ECM Degradation
Top
 Abstract
 Introduction
 Role of Plasminogen Activator...
Conclusion
 References
 
Two major ECM protease systems, plasminogen activator (PA)/plasmin/PA inhibitors (PAI) system and matrix metalloproteinases (MMP)/tissue inhibitors of matrix metalloproteinases (TIMP) system, are interrelated and involved in matrix degradation (13–15). The physiology of each system is complex, and the activities are tightly regulated at many levels, including gene expression, activation, and inhibition by specific inhibitors (Figure 2). Plasmin is generated from plasminogen by the enzymatic activity of tissue-type PA (tPA) and urokinase-type PA (uPA). PA activity is inhibited by PAI. A strong positive correlation between plasmin activity and ECM degradation in cultured mesangial cells and the ability of plasmin inhibitors to inhibit ECM degradation suggest the importance of plasmin in ECM degradation by mesangial cells (16). Plasmin not only degrades several matrix proteins such as fibronectin, laminin, proteoglycan, and type IV collagen (17–19) but also activates pro-MMP (20,21). PAI-1 seems to play an important role in ECM degradation in mesangial cells, because a larger molar excess of PAI-1 over tPA and uPA is detected in mesangial cell culture supernatant and because anti-PAI-1 antibody increases ECM degradation (22). PAI-1 is not expressed in normal human kidney but is strongly induced in various forms of kidney diseases that lead to renal fibrosis and is now considered a potential target in renal fibrogenesis (23).



View larger version (16K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Figure 2. ECM protease systems in diabetic kidney.

 
Both high glucose (24) and TGF-{beta}1 (24,25) upregulate PAI-1 mRNA and protein expression in a time-dependent manner and decrease plasmin activity in glomerular mesangial cells. TGF-{beta}1 also increases PAI-1 protein synthesis and decreases PA activity in normal as well as diseased glomeruli (26) and in rat proximal tubular epithelial cells (27). TGF-{beta}1 markedly reduces the conversion of latent MMP-2 to active form, leading to decreased ECM degradation in human mesangial cells (25). High glucose decreases MMP and increases TIMP expression possibly through TGF-{beta}1 (28). These observations suggest that high glucose, directly or indirectly through TGF-{beta}1, upregulates PAI-1 and decreases plasmin activity and ECM degradation in renal cells. Our preliminary observation (24) suggests that ROS may play a critical role in both high glucose- and TGF-{beta}1-induced PAI-1 expression and decreased plasmin activity.

ROS Upregulate PAI-1 Expression and Downregulate Plasmin Activity
High glucose, TGF-{beta}1, and H2O2 continuously generated by glucose oxidase (GO) upregulate PAI-1 mRNA expression and protein secretion and significantly suppress plasmin activity in rat mesangial cells (24). When cells were pretreated with DL-buthionine-(S,R)-sulfoximine (BSO) for 24 h to deplete the intracellular glutathione, basal PAI-1 expression was upregulated; plasmin activity was downregulated; and high glucose-, TGF-{beta}1-, and GO-induced PAI-1 mRNA expression and protein secretion were exaggerated. In addition, antioxidants N-acetylcysteine (NAC), catalase, and trolox effectively reverse high glucose-, TGF-{beta}1-, and GO-induced changes in PAI-1 mRNA and protein expression and plasmin activity without significant effect on basal expression. In this study, TGF-{beta}1 at concentrations that upregulated PAI-1 expression increased intracellular ROS in mesangial cells. These observations suggest that ROS mediate high glucose- and TGF-{beta}1-induced upregulation of PAI-1 mRNA expression and protein secretion, leading to decreased plasmin activity in mesangial cells (24). Previous studies demonstrated that ROS mediate hyperglycemia-induced (29) and cyclic strain-induced (30) PAI-1 expression in endothelial cells and radiation-induced PAI-1 expression in rat kidney tubular epithelial cells (31).

ROS Induce EMT in Tubular Epithelial Cells
Yang and Liu (4) demonstrated that EMT is an orchestrated, highly regulated process involving four key steps: (1) loss of epithelial cell adhesion, (2) de novo {alpha}-smooth muscle actin expression and actin reorganization, (3) disruption of tubular basement membrane, and (4) enhanced cell migration and invasion into the interstitium. Although EMT can be induced by TGF-{beta}1 (32), AGE (33), and Ang II (34), the intracellular signaling pathways that lead to EMT remain largely unknown. Smad pathway (32), c-jun-NH2-terminal kinase (JNK) (35), and p38 mitogen-activated protein kinase (MAPK) (36) seem to be involved in TGF-{beta}1-induced EMT. In normal rat tubular epithelial cell line NRK-52E, Li et al. (32) showed that TGF-{beta}1 induced Smad2 phosphorylation and resulted in the transformation of epithelial cell into myofibroblast phenotype with the loss of E-cadherin and de novo expression of {alpha}-smooth muscle actin and collagens I, III, and IV and that overexpression of Smad7 resulted in marked inhibition of TGF-{beta}-induced Smad2 activation with the prevention of EMT and collagen synthesis. Hashimoto et al. (35) showed that a specific inhibitor of JNK-mediated signaling pathway (CEP-1347) but not an inhibitor of ERK (PD 98059) or p38 MAPK (SB 203580) attenuated TGF-{beta}1-induced phenotypic modulation of human lung fibroblasts. In mouse mammary epithelial cells, however, p38 MAPK is required for TGF-{beta}-mediated fibroblastic transdifferentiation and cell migration (36). Bakin et al. (36) showed that a direct inhibitor of p38 MAPK inhibited TGF-{beta}-mediated changes in cell shape and reorganization of the actin cytoskeleton and that dominant negative MAPK kinase 3 (MKK3) inhibited TGF-{beta}-mediated activation of p38 MAPK and EMT. We (11) recently observed that exogenous H2O2 as well as TGF-{beta}1 induces EMT in tubular epithelial cells and that antioxidants NAC and catalase effectively inhibit TGF-{beta}1-induced EMT. These data suggest that ROS may also play an important role in induction of EMT leading to tubulointerstitial fibrosis in diabetic kidney. It is not known whether ROS are involved in Smad activation or in JNK or p38 MAPK activation leading to EMT.

Whereas decreased ECM degradation plays an important role in ECM deposition in the kidney, accelerated ECM degradation is required during the process of EMT to effectively disrupt tubular basement membrane. In this regard, Yang et al. (5) demonstrated that deficiency of tPA in mice selectively block EMT and significantly decrease MMP-9 induction, leading to a dramatic preservation of the structural and functional integrity of tubular basement membrane and that disruption of tPA gene reduced deposition of interstitial collagen III and fibronectin as well as total tissue collagen in the kidneys after sustained ureteral obstruction. This study underscores the importance of ECM degradation to complete EMT. The role of ROS in increased ECM degradation is suggested by the observation that v-Ha-Ras oncogene induces ROS generation, NF-{kappa}B activation, and upregulation of MMP-9 mRNA along with downregulation of TIMP-1, an inhibitor of MMP-9, and PAI-1 mRNA in tubular epithelial cells (37).


   Conclusion
Top
 Abstract
 Introduction
 Role of Plasminogen Activator...
 Conclusion
References
 
Diabetes favors ECM accumulation in the kidney during remodeling process. High glucose and TGF-{beta}1 increase ECM synthesis and secretion and at the same time decrease ECM degradation by inhibiting proteolytic systems plasmin and MMP in the glomeruli through ROS. However, ROS mediate TGF-{beta}1-induced EMT through increasing MMP activity and ECM degradation in tubular epithelial cells, leading to tubulointerstitial fibrosis. It is not clear how cells determine when and where to increase or decrease ECM degradation in response to ROS. More precise definition of ROS-activated signaling pathways leading to ECM remodeling in the kidney will provide us with new strategies to treat diabetic renal injury.


   Acknowledgments
 
The original works performed in the authors’ laboratory were supported by a grant from the Korea Research Foundation (KRF 1999-005-F00025).


   References
Top
 Abstract
 Introduction
 Role of Plasminogen Activator...
 Conclusion
 References
 

  1. Steffes MW, Osterby R, Chavers B, Mauer M: Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes 38: 1077–1081, 1984
  2. Gilbert RE, Cooper ME: The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury? Kidney Int 56: 1627–1637, 1999[CrossRef][Medline]
  3. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339: 69–75, 1998[Abstract/Free Full Text]
  4. Yang J, Liu Y: Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol 159: 1465–1475, 2001[Abstract/Free Full Text]
  5. Yang J, Shultz RW, Mars WM, Rodney E, Wegner RE, Li Y, Dai C, Nejak K, Liu Y: Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J Clin Invest 110: 1525–1538, 2002[CrossRef][Medline]
  6. Lan HY: Tubular epithelial-myofibroblast transdifferentiation mechanism in proximal tubule cells. Curr Opin Nephrol Hypertens 12: 25–29, 2003[CrossRef][Medline]
  7. Ha H, Yu MR, Choi YJ, Kitamura M, Lee HB: Role of high glucose-induced nuclear factor-{kappa}B activation in monocyte chemoattractant protein-1 expression by mesangial cells. J Am Soc Nephrol 13: 894–902, 2002[Abstract/Free Full Text]
  8. Scivittaro V, Ganz MB, Weiss MF: AGEs induce oxidative stress and activate protein kinase C-{beta}II in neonatal mesangial cells. Am J Physiol 278: F676–F683, 2000
  9. Yamagishi S-I, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M: Advanced glycation end products inhibit de novo protein synthesis and induce TGF-{beta} overexpression in proximal tubular cells. Kidney Int 63: 464–473, 2003[CrossRef][Medline]
  10. Jaimes EA, Galceran JM, Raij L: Angiotensin II induces superoxide anion production by mesangial cells. Kidney Int 54: 775–784, 1998[CrossRef][Medline]
  11. Yang Y, Ha H, Lee HB: Role of reactive oxygen species in TGF-{beta}1-induced epithelial-mesenchymal transition [Abstract]. Nephrol Dial Transplant 18 [Suppl 4]: 300, 2003
  12. Ha H, Lee HB: Reactive oxygen species as glucose signaling molecules in mesangial cells cultured under high glucose. Kidney Int 58 [Suppl 77]: S19–S25, 2000
  13. Mignatti P: Extracellular matrix remodeling by metalloproteinases and plasminogen activators. Kidney Int 47 [Suppl 49]: S12–S14, 1995
  14. Schnaper HW: Balance between matrix synthesis and degradation: A determinant of glomerulosclerosis. Pediatr Nephrol 9: 104–111, 1995[CrossRef][Medline]
  15. Stetler-Stevenson WG: Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am J Pathol 148: 1345–1350, 1996[Medline]
  16. Wong AP, Cortez SL, Baricos WH: Role of plasmin and gelatinase in extracellular matrix degradation by cultured rat mesangial cells. Am J Physiol 263: F1112–F1118, 1992
  17. Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V, Garbisa S: Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 41: 4629–4636, 1981
  18. Mochan E, Keler T: Plasmin degradation of cartilage proteoglycan. Biochim Biophys Acta 800: 312–315, 1984[Medline]
  19. Mackay AR, Corbitt RH, Hartzler JL, Thorgeirsson UP: Basement membrane type IV collagen degradation: Evidence for the involvement of a proteolytic cascade independent of metalloproteinases. Cancer Res 50: 5997–6001, 1990[Abstract/Free Full Text]
  20. He C, Wilhelm SM, Pentland AP, Marmer BL, Grant GA, Eisen AZ, Goldberg GI: Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci U S A 86: 2632–2636, 1989[Abstract/Free Full Text]
  21. Nagase H, Enghild JJ, Suzuki K, Salvesen G: Stepwise activation mechanism of the precursor of matrix metalloproteinase 3 (stromolysin) by proteinases and (4-aminophenyl) mercuric acetate. Biochemistry 29: 5783–5789, 1990[CrossRef][Medline]
  22. Baricos WH, Cortes SL, El-Dahar SS, Schnaper W: ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. Kidney Int 47: 1039–1047, 1995[Medline]
  23. Rerolle JP, Hertig A, Nguyen G, Sraer JD, Rondeau EP: Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int 58: 1841–1850, 2000[CrossRef][Medline]
  24. Lee HB, Seo J, Jiang Z, Ha H: Reactive oxygen species mediate high glucose- and TGF-{beta}1-induced upregulation of plasminogen activator inhibitor-1 expression in mesangial cells [Abstract]. European Diabetic Nephropathy Study Group 15th Meeting, Barcelona-Catalunya, Spain, May 2–4, 2002
  25. Baricos WH, Cortez SL, Deboisblanc M, Xin S: Transforming growth factor-beta is a potent inhibitor of extracellular matrix degradation by cultured human mesangial cells. J Am Soc Nephrol 10: 790–795, 1999[Abstract/Free Full Text]
  26. Tamooka S, Border WA, Marshall BC, Noble NA: Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int 42: 1462–1469, 1992[Medline]
  27. Kanalas JJ, Hopfer U: Effect of TGF-{beta}1 and TNF-{alpha} on the plasminogen system of rat proximal tubular epithelial cells. J Am Soc Nephrol 8: 184–192, 1997[Abstract]
  28. McLennan SV, Fisher E, Martell SY, Death AK, Williams PF, Lyons JG, Yue DK: Effects of glucose on matrix metalloproteinase and plasmin activities in mesangial cells: Possible role in diabetic nephropathy. Kidney Int 58 [Suppl 77]: S81–S87, 2000
  29. Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Wu J, Brownlee M: Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A 97: 12222–12226, 2000[Abstract/Free Full Text]
  30. Cheng JJ, Chao YJ, Wung BS, Wang DL: Cyclic strain-induced plasminogen activator inhibitor-1 (PAI-1) release from endothelial cells involves reactive oxygen species. Biochem Biophys Res Commun 225: 100–105, 1996[CrossRef][Medline]
  31. Zhao W, Spitz DR, Oberley LW, Robbins ME: Redox modulation of the pro-fibrogenic mediator plasminogen activator inhibitor-1 following ionizing radiation. Cancer Res 61: 5537–5543, 2001[Abstract/Free Full Text]
  32. Li JH, Zhu HJ, Huang XR: Smad7 inhibits fibrotic effect of TGF-{beta} on renal tubular epithelial cells by blocking smad2 activation. J Am Soc Nephrol 13: 1464–1472, 2002[Abstract/Free Full Text]
  33. Oldfield MD, Bach LS, Forbes JM, Nikolic-Pateerson D, McRobert A, Thallas V, Atkins RC, Osicka T, Jerums G, Cooper ME: Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest 108: 1853–1863, 2001[CrossRef][Medline]
  34. Hunag XR, Li JH, Chen YX, Johnson RJ, Lan HY: SMAD signaling, a novel pathway of angiotensin II-induced renal fibrosis [Abstract]. J Am Soc Nephrol 12: 465A, 2001
  35. Hashimoto S, Gon Y, Takeshita I, Matsumoto K, Maruoka S, Horie T: Transforming growth factor-{beta}1 induces phenotypic modulation of human lung fibroblasts to myofibroblast through a c-jun-NH2-terminal kinase-dependent pathway. Am J Respir Crit Care Med 163: 152–157, 2001[Abstract/Free Full Text]
  36. Bakin AV, Rinehart C, Tomlinson AK, Arteaga CL: p38 mitogen-activated protein kinase is required for TGF-{beta}-mediated fibroblastic transdifferentiation and cell migration. J Cell Sci 115: 3193–3206, 2002[Abstract/Free Full Text]
  37. Yang J-Q, Zhao W, Duan H, Robbins MEC, Buettner GR, Oberley LW, Domann FE: v-Ha-Ras oncogene upregulates the 92-kDa type IV collagenase (MMP-9) gene by increasing cellular superoxide production and activating NF-{kappa}B. Free Radic Biol Med 31: 520–529, 2001[CrossRef][Medline]



This article has been cited by other articles:


Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
M. Li, X. Dai, S. Watts, D. Kreulen, and G. Fink
Increased superoxide levels in ganglia and sympathoexcitation are involved in sarafotoxin 6c-induced hypertension
Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2008; 295(5): R1546 - R1554.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
J. Holian, W. Qi, D. J. Kelly, Y. Zhang, E. Mreich, C. A. Pollock, and X.-M. Chen
Role of Kruppel-like factor 6 in transforming growth factor-{beta}1-induced epithelial-mesenchymal transition of proximal tubule cells
Am J Physiol Renal Physiol, November 1, 2008; 295(5): F1388 - F1396.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
P. Chitano, L. Wang, S. N. Mason, R. L. Auten, E. N. Potts, W. M. Foster, A. Sturrock, T. P. Kennedy, J. R. Hoidal, and T. M. Murphy
Airway smooth muscle relaxation is impaired in mice lacking the p47phox subunit of NAD(P)H oxidase
Am J Physiol Lung Cell Mol Physiol, January 1, 2008; 294(1): L139 - L148.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
A. Djamali
Oxidative stress as a common pathway to chronic tubulointerstitial injury in kidney allografts
Am J Physiol Renal Physiol, August 1, 2007; 293(2): F445 - F455.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
A. Djamali, E. A. Sadowski, R. J. Muehrer, S. Reese, C. Smavatkul, A. Vidyasagar, S. B. Fain, R. C. Lipscomb, D. H. Hullett, M. Samaniego-Picota, et al.
BOLD-MRI assessment of intrarenal oxygenation and oxidative stress in patients with chronic kidney allograft dysfunction
Am J Physiol Renal Physiol, February 1, 2007; 292(2): F513 - F522.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
W. C. Burns, S. M. Twigg, J. M. Forbes, J. Pete, C. Tikellis, V. Thallas-Bonke, M. C. Thomas, M. E. Cooper, and P. Kantharidis
Connective Tissue Growth Factor Plays an Important Role in Advanced Glycation End Product-Induced Tubular Epithelial-to-Mesenchymal Transition: Implications for Diabetic Renal Disease
J. Am. Soc. Nephrol., September 1, 2006; 17(9): 2484 - 2494.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
V. Dasari, M. Gallup, H. Lemjabbar, I. Maltseva, and N. McNamara
Epithelial-Mesenchymal Transition in Lung Cancer: Is Tobacco the "Smoking Gun"?
Am. J. Respir. Cell Mol. Biol., July 1, 2006; 35(1): 3 - 9.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
L. Xia, H. Wang, H. J. Goldberg, S. Munk, I. G. Fantus, and C. I. Whiteside
Mesangial cell NADPH oxidase upregulation in high glucose is protein kinase C dependent and required for collagen IV expression
Am J Physiol Renal Physiol, February 1, 2006; 290(2): F345 - F356.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
J. B. de Haan, N. Stefanovic, D. Nikolic-Paterson, L. L. Scurr, K. D. Croft, T. A. Mori, P. Hertzog, I. Kola, R. C. Atkins, and G. H. Tesch
Kidney expression of glutathione peroxidase-1 is not protective against streptozotocin-induced diabetic nephropathy
Am J Physiol Renal Physiol, September 1, 2005; 289(3): F544 - F551.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ha, H.
Right arrow Articles by Lee, H. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ha, H.
Right arrow Articles by Lee, H. B.

HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP